The terms of the transaction were not disclosed, but the FT reports that the deal will value the business at around €2bn.
The talks come after the two firms sold a partial stake in Sebia to Caisse de Dépôt et Placement du Québec (CDPQ), the Canadian institutional asset manager, in August. This transaction will provide a complete exit from the business.
Founded in 1967, Sebia provides clinical protein electrophoresis equipment and reagents, a technology used for in-vitro diagnostic testing. Its systems analyse proteins in order to screen and monitor various diseases and conditions. The company is headquartered in Lisses, France, and operates across more than 120 countries.
During Montagu and Astorg’s hold the company has grown in the myeloma diagnosis space and entered the diabetes market. The business also acquired Italian group Interlab. The group is chaired by Benoît Adelus.
The deal is subject to workers’ council information and consultation and regulatory clearance.